Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,095 shares of the biopharmaceutical company’s stock after buying an additional 4,806 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.08% of Ultragenyx Pharmaceutical worth $4,338,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth approximately $28,000. nVerses Capital LLC acquired a new position in Ultragenyx Pharmaceutical in the second quarter valued at $33,000. UMB Bank n.a. raised its holdings in shares of Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 352 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 67.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 1,339 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 140.9% during the first quarter. Lazard Asset Management LLC now owns 4,160 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,433 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 0.2 %

RARE stock opened at $54.69 on Thursday. The company’s 50-day moving average price is $55.97 and its 200 day moving average price is $47.71. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $60.37. The company has a market cap of $5.04 billion, a P/E ratio of -7.49 and a beta of 0.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.12. The company had revenue of $147.03 million during the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company’s revenue for the quarter was up 35.7% on a year-over-year basis. During the same period last year, the firm earned ($2.25) EPS. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the transaction, the chief executive officer now directly owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,556 shares of company stock worth $2,519,367. 5.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on RARE. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. TD Cowen upped their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Wells Fargo & Company raised their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.29.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.